In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

At Axtria Ignite 2025 in Princeton, New Jersey, web editor Nicole Raleigh spoke with the company’s co-founder, president, and CEO Jaswinder Chadha. An AI-first data analytics innovator focused on ...

Faced with the prospect of tariffs on imported medicines threatened by the Trump administration, Indian drugmaker Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Together, these policies signal a new era of pricing accountability and regulatory oversight, with significant implications for drug development strategies, market access, and patient affordability.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...